Cargando…

Advantages of Tyrosine Kinase Anti-Angiogenic Cediranib over Bevacizumab: Cell Cycle Abrogation and Synergy with Chemotherapy

Angiogenesis plays a crucial role in tumor development and metastasis. Both bevacizumab and cediranib have demonstrated activity as single anti-angiogenic agents in endometrial cancer, though subsequent studies of bevacizumab combined with chemotherapy failed to improve outcomes compared to chemothe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bi, Jianling, Dixit, Garima, Zhang, Yuping, Devor, Eric J., Losh, Haley A., Newtson, Andreea M., Coleman, Kristen L., Santillan, Donna A., Maretzky, Thorsten, Thiel, Kristina W., Leslie, Kimberly K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8308742/ https://www.ncbi.nlm.nih.gov/pubmed/34358108 http://dx.doi.org/10.3390/ph14070682

Ejemplares similares

Blocking autophagy overcomes resistance to dual histone deacetylase and proteasome inhibition in gynecologic cancer
por: Bi, Jianling, et al.
Publicado: (2022)

Successful Patient-Derived Organoid Culture of Gynecologic Cancers for Disease Modeling and Drug Sensitivity Testing
por: Bi, Jianling, et al.
Publicado: (2021)

Cediranib with mFOLFOX6 vs bevacizumab with mFOLFOX6 in previously treated metastatic colorectal cancer
por: Cunningham, D, et al.
Publicado: (2013)

Prognostic and predictive value of VEGF, sVEGFR-2 and CEA in mCRC studies comparing cediranib, bevacizumab and chemotherapy
por: Jürgensmeier, J M, et al.
Publicado: (2013)

Immune Mechanisms of Resistance to Cediranib in Ovarian Cancer
por: Gopinathan, Ganga, et al.
Publicado: (2022)

Multi-Center Randomized Phase II Study Comparing Cediranib plus Gefitinib with Cediranib plus Placebo in Subjects with Recurrent/Progressive Glioblastoma
por: Brown, Nicholas, et al.
Publicado: (2016)

Early changes in glioblastoma metabolism measured by MR spectroscopic imaging during combination of anti-angiogenic cediranib and chemoradiation therapy are associated with survival
por: Andronesi, Ovidiu C., et al.
Publicado: (2017)

Members of the Fibroblast Growth Factor Receptor Superfamily Are Proteolytically Cleaved by Two Differently Activated Metalloproteases
por: Dixit, Garima, et al.
Publicado: (2021)

Identification of Novel Fusion Transcripts in High Grade Serous Ovarian Cancer
por: Newtson, Andreea, et al.
Publicado: (2021)

FGFR2 mutations promote endometrial cancer progression through dual engagement of EGFR and Notch signalling pathways
por: Dixit, Garima, et al.
Publicado: (2023)

Functional Distinctions of Endometrial Cancer-Associated Mutations in the Fibroblast Growth Factor Receptor 2 Gene
por: Dixit, Garima, et al.
Publicado: (2023)

The Threshold Effect: Lipopolysaccharide-Induced Inflammatory Responses in Primary Macrophages Are Differentially Regulated in an iRhom2-Dependent Manner
por: Skurski, Joseph, et al.
Publicado: (2021)

Randomized Phase II Trial of Sunitinib or Cediranib in Alveolar Soft Part Sarcoma
por: Nguyen, James, et al.
Publicado: (2023)

Unraveling the Synergy between Atezolizumab and Bevacizumab for the Treatment of Hepatocellular Carcinoma
por: Brackenier, Cedric, et al.
Publicado: (2023)

Prognostic/predictive value of 207 serum factors in colorectal cancer treated with cediranib and/or chemotherapy
por: Spencer, S K M, et al.
Publicado: (2013)

Synergistic Antivascular and Antitumor Efficacy with Combined Cediranib and SC6889 in Intracranial Mouse Glioma
por: Lobo, Merryl R., et al.
Publicado: (2015)

Hypercholesterolemia-induced increase in plasma oxidized LDL abrogated pro angiogenic response in kidney grafts
por: Kerforne, Thomas, et al.
Publicado: (2019)

Combined Efficacy of Cediranib and Quinacrine in Glioma Is Enhanced by Hypoxia and Causally Linked to Autophagic Vacuole Accumulation
por: Lobo, Merryl R., et al.
Publicado: (2014)

Identification of target genes of cediranib in alveolar soft part sarcoma using a gene microarray
por: Jiang, Wenhua, et al.
Publicado: (2017)

Reply to comment on: “Advantages of bevacizumab for aggressive posterior retinopathy of prematurity”
por: Schechet, Sidney A., et al.
Publicado: (2019)

Beyond Bevacizumab: An Outlook to New Anti-Angiogenics for the Treatment of Ovarian Cancer
por: Mahner, Sven, et al.
Publicado: (2015)

Identification of Novel lncRNAs in Ovarian Cancer and Their Impact on Overall Survival
por: Cardillo, Nicholas, et al.
Publicado: (2021)

Long-term Remission Over Six Years for a Patient with Recurrent Glioblastoma Treated with Cediranib/Lomustine
por: Drazin, Doniel, et al.
Publicado: (2016)

Quality of life with cediranib in relapsed ovarian cancer: The ICON6 phase 3 randomized clinical trial
por: Stark, Dan P., et al.
Publicado: (2017)

Population Substructure Has Implications in Validating Next-Generation Cancer Genomics Studies with TCGA
por: Miller, Marina D., et al.
Publicado: (2019)

Plant proteolytic enzyme papain abrogates angiogenic activation of human umbilical vein endothelial cells (HUVEC) in vitro
por: Mohr, Thomas, et al.
Publicado: (2013)

Fibrocyte-like cells mediate acquired resistance to anti-angiogenic therapy with bevacizumab
por: Mitsuhashi, Atsushi, et al.
Publicado: (2015)

Predictive value of angiogenic proteins in patients with metastatic melanoma treated with bevacizumab monotherapy
por: Schuster, Cornelia, et al.
Publicado: (2018)

Molecular Characterization of Non-responders to Chemotherapy in Serous Ovarian Cancer
por: McDonald, Megan E., et al.
Publicado: (2019)

Creation and validation of models to predict response to primary treatment in serous ovarian cancer
por: Gonzalez Bosquet, Jesus, et al.
Publicado: (2021)

Clinical Activity and Safety of Cediranib and Olaparib Combination in Patients with Metastatic Pancreatic Ductal Adenocarcinoma without BRCA Mutation
por: Kim, Joseph W., et al.
Publicado: (2021)

Interval debulking surgery is not worth the wait: a National Cancer Database study comparing primary cytoreductive surgery versus neoadjuvant chemotherapy
por: Lyons, Yasmin A, et al.
Publicado: (2020)

Unexpectedly durable palliation of metastatic olfactory neuroblastoma using anti-angiogenic therapy with Bevacizumab
por: Dunbar, Erin M., et al.
Publicado: (2012)

Pulmonary tumor thrombotic microangiopathy and pulmonary veno-occlusive disease in a woman with cervical cancer treated with cediranib and durvalumab
por: Suffredini, Dante A., et al.
Publicado: (2018)

Circulating biomarkers during treatment in patients with advanced biliary tract cancer receiving cediranib in the UK ABC-03 trial
por: Backen, Alison C., et al.
Publicado: (2018)

Combination of triapine, olaparib, and cediranib suppresses progression of BRCA-wild type and PARP inhibitor-resistant epithelial ovarian cancer
por: Lin, Z. Ping, et al.
Publicado: (2018)

Vitamin D Enhances Anticancer Properties of Cediranib, a VEGFR Inhibitor, by Modulation of VEGFR2 Expression in Melanoma Cells
por: Piotrowska, Anna, et al.
Publicado: (2021)

Differential DNA methylation in high-grade serous ovarian cancer (HGSOC) is associated with tumor behavior
por: Reyes, Henry D., et al.
Publicado: (2019)

Integrated Clinical and Genomic Models to Predict Optimal Cytoreduction in High-Grade Serous Ovarian Cancer
por: Cardillo, Nicholas, et al.
Publicado: (2022)

Selective Inhibition of Membrane Type 1 Matrix Metalloproteinase Abrogates Progression of Experimental Inflammatory Arthritis: Synergy With Tumor Necrosis Factor Blockade
por: Kaneko, Kazuyo, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_ic3qm5d75coc3o8o3bg45ae72q